New Medicine - A Comprehensive Information and Consulting Service  
HOME PRODUCTS & SERVICES ORDER/INQUIRY PRESS RELEASES EMPLOYMENT CONTACT US

FUTURE ONCOLOGY
Volume 3 # 6 October 1997
State-of the-Art in the Management of Cancer

Head and Neck Cancer-Part III
Novel Therapeutic and chemopreventive Approaches in Development

Commercially Available Agents in Clinical Trials in HNSCC

  • Gemcitabine
  • Vinorelbine
  • Taxanes

Novel Chemotherapeutics

Thymidylate Synthase Inhibitors

  • Nolatrexed

Retinoids

  • ALRT1550

Gene Therapy

p53

  • Introgen Therapeutics

p16

Herpes Simplex Thymidine Kinase

Onyx-015

HPV

Growth Factors/Cytokines

Epidermal Growth Factor (EGF) Receptor Inhibitors

  • Quinazolines
  • C225
  • MDX-447
  • MAb ICR62

Interferon as Adjuvant Therapy

Tumor Necrosis Factor a (TNF-a )

Immunotherapy/Vaccines

  • Cel-Sci
  • Gene Medicine

University of Pittsburgh

Radiosensitization

  • Enzon

Hypoxic Cells

Vion Pharmaceuticals

Pharmacyclics

Management of Treatment-related Complications

Ethyol

Lysophylline

Hyal Pharmaceutical

Drug Delivery

Genetronics

Chemoprevention

Meeting Coverage

OPPORTUNISTIC INFECTIONS IN IMMUNOCOMPROMISED PATIENTS

From the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Toronto, Ontario, Canada, September 28-October 1, 1997

Bacterial Infections

Risk Factors For Gram-Positive Infections

Capnacytophaga Bacteremia

The Growing Problem of Vancomycin-Resistant Enterococci

  • Quinupristin/dalfopristin
  • LY 333328
  • Daptomycin
  • Linezolid
  • Ziracin
  • Other agents

Vancomycin-Intermediate Staphylococcus aureus

Methicillin-resistant Staphylococcus aureus

Other Bacterial Infections in Cancer Patients

  • Penicillin-resistant Streptococcus pneumoniae
  • Stenotrophomonas maltophilia
  • Pseudomonas aeruginosa

Fungal Infections

  • Candida Fungi
  • Zygomycosis
  • Fusarium

Antifungals in Development

  • Nyotran
  • Echinocandin derivatives
  • SCH 56592
  • Sordaricin derivatives

Novel Antifungal R&D Programs

  • RiboGene
  • Myco Pharmaceuticals
  • Alpha-Beta Technology

Therapeutic Approaches for Opportunistic Infections

Bacterial Infections

  • Cefepime
  • Ciprofloxacin

Viral Infections

  • Peniclovir

 

Fungal Infections

Liposomal amphotericin B

Aerosol amphotericin B prophylaxis

Fluconazole

Granulocyte-macrophage colony stimulating factor

Voriconazole

Itraconazole oral solution

Azole-based prophylaxis

 

New Spectrum of Opportunistic Infections in Fludarabine-Treated CLL

Fungal Pneumonia

 

Costs Associated with Anti-infective Therapy in Neutropenic Patients


HOME | PRODUCTS & SERVICES | ORDER/INQUIRY | PRESS RELEASES | EMPLOYMENT | CONTACT US

NEW MEDICINE, INC.
PHONE: 949-830-0448   FAX: 949-830-0887